What is Zacks Research’s Forecast for AGIO FY2025 Earnings?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities research analysts at Zacks Research lifted their FY2025 earnings estimates for shares of Agios Pharmaceuticals in a research report issued to clients and investors on Monday, November 10th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn ($7.32) per share for the year, up from their previous forecast of ($7.52). Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($2.06) EPS, Q1 2026 earnings at ($1.85) EPS, Q2 2026 earnings at ($1.97) EPS, Q3 2026 earnings at ($1.94) EPS, Q4 2026 earnings at ($1.86) EPS, FY2026 earnings at ($7.61) EPS, Q1 2027 earnings at ($1.58) EPS, Q2 2027 earnings at ($1.64) EPS, Q3 2027 earnings at ($1.67) EPS and FY2027 earnings at ($6.50) EPS.

Other research analysts also recently issued reports about the company. Weiss Ratings downgraded Agios Pharmaceuticals from a “hold (c-)” rating to a “sell (d)” rating in a research note on Friday. Scotiabank dropped their target price on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a report on Monday, July 28th. Bank of America reduced their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. HC Wainwright reissued a “buy” rating and issued a $56.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Finally, Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $57.25.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $43.86 on Wednesday. The stock’s 50 day simple moving average is $39.94 and its 200-day simple moving average is $36.51. The company has a market cap of $2.56 billion, a PE ratio of -6.27 and a beta of 0.89. Agios Pharmaceuticals has a 1-year low of $23.42 and a 1-year high of $62.45.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The company had revenue of $12.90 million during the quarter, compared to analyst estimates of $10.49 million. During the same period in the previous year, the business earned $16.22 EPS. Agios Pharmaceuticals’s quarterly revenue was up 43.3% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. NewEdge Advisors LLC purchased a new stake in Agios Pharmaceuticals in the first quarter valued at $40,000. First Horizon Corp acquired a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth about $45,000. CWM LLC increased its position in shares of Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 996 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Agios Pharmaceuticals by 16.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 320 shares during the period. Finally, PNC Financial Services Group Inc. lifted its position in Agios Pharmaceuticals by 16.2% in the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 499 shares during the last quarter.

Insider Buying and Selling

In other news, insider Theodore James Jr. Washburn sold 8,546 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $36.87, for a total value of $315,091.02. Following the completion of the sale, the insider owned 868 shares of the company’s stock, valued at $32,003.16. This represents a 90.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Sarah Gheuens sold 3,302 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $43.92, for a total transaction of $145,023.84. Following the sale, the insider owned 61,727 shares of the company’s stock, valued at $2,711,049.84. This represents a 5.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 15,899 shares of company stock worth $611,324. Insiders own 4.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.